Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 8.7× sales vs its 3.7× historical median P/S.
Fair value ≈ $8.07 · price $18.96 today
Overvalued · 135% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$BTC $ETH $VVV $MOR $USD1
VVV and MOR tokens jumped after the US pushed Anthropic to block foreign access to its new AI models. Here is why traders reacted fast.
https://www.thecryptofire.com/p/anthropic-ai-block-sends-vvv-mor-tokens-into-rally
@longrigger52 @seforim right, like they paid how much for $mor and need more studies? Well, we are enrolling in our p3, larger audience 70% of MF and we are at what market cap? WTF
$HOOK replaced both CEO and CFO last week!
"Dr. Peters and Ms. Coelho are the right leaders for this next stage ....with the aim of ensuring value for shareholders."
"Dr. Peters is a seasoned executive with deep experience in bringing new therapies to patients and most recently served as Chief Research and Development Officer at MorphoSys $MOR, while Ms. Coelho is a proven CFO with significant expertise in business development, finance, and M&A who most recently served as CFO for Gamida Cell $GMDA"
bye Jorn...
https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-announces-leadership-changes-intensify-focus-hb
$HMR SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates $ALLG, $MOR, $BEST, MGOL on Behalf of Shareholders.
NEW YORK, June 29, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
https://halpersadeh.com/actions/mgo-global-inc
$MOR $NVS MorphoSys and Novartis sign delisting agreement
MorphoSys (MOR) has entered into a delisting agreement with Novartis (NVS) following the successful closing of the acquisition of MorphoSys by Novartis in May. Novartis BidCo Germany AG also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders EUR68.00 per share in cash.
As of June 20, Novartis holds approximately 91.04% of the total MorphoSys share capital. As a result, Novartis is the majority shareholder of MorphoSys, making MorphoSys a Novartis company. Novartis intends to launch a public delisting purchase offer for all outstanding MorphoSys no-par value bearer shares. Novartis will offer MorphoSys shareholders EUR 68.00 per share in cash. The Delisting Offer document is expected to be published by Novartis in early July.
Once the Delisting Offer document is published by Novartis, a four-week offer period for MorphoSys shareholders to tender their shares will commence. After the delisting becomes effective, MorphoSys shares will no longer be traded on the regulated market of the Frankfurt Stock Exchange or on NASDAQ. Both the delisting from the Frankfurt Stock Exchange and the delisting from NASDAQ are expected to take place in Q3. Novartis also informed MorphoSys of their intention to merge MorphoSys into Novartis.
Given Novartis holds approximately 91.04% of the total MorphoSys share capital, Novartis is able to facilitate a squeeze-out of MorphoSys' minority shareholders in connection with such a merger. Novartis will therefore seek the transfer of MorphoSys' minority shareholders' shares to Novartis against an adequate cash compensation. The amount of the cash compensation has not yet been determined. It is planned that the necessary shareholders' resolution on the merger squeeze-out will be adopted at the MorphoSys Annual General Meeting expected to take place in August.
$NVS $MOR here we go again, Fudstein doing a last minute bashing! What can he do, friends need to close their short positions urgently. Price is above the buyout offer for days now, Novartis getting extra money from Hi bio buyout.
Things are getting desperate, losses probably huge.
https://www.statnews.com/2024/06/04/novartis-morphosys-myelofibrosis-pelabresib/
$MOR here we go again, Fudstein doing a last minute bashing! What can he do, friends need to close their short positions urgently. Price is above the buyout offer for days now, Novartis getting extra money from Hi bio buyout. Things are getting desperate, losses probably huge. https://www.statnews.com/2024/06/04/novartis-morphosys-myelofibrosis-pelabresib/
$MOR so NVS gets also 15% of 1.15 B from this: https://www.morphosys.com/en/news/morphosys-and-hibio-enter-equity-participation-and-license-agreements-felzartamab-and-mor210
$MOR I accepted the tender offer last Friday. Now the market price is over $19 US? Wonder if I’ll get less than current market price, which I thought would be in the 18s. Guess so? And not understanding the surge either.
$MOR $NVS Novartis meets all tender offer conditions to acquire MorphoSys
Novartis BidCo AG, an indirect wholly owned subsidiary of Novartis AG (NVS), announced the result of its voluntary public takeover offer for the shares of MorphoSys AG (MOR), including all shares represented by MorphoSys American Depositary Shares, or "ADS.". As of the expiry of the acceptance period at 24:00 hours CEST on May 13, the offer has been accepted by approximately 79.6% of the total share capital of MorphoSys, including purchases by Novartis BidCo AG outside the offer for approximately 11.6% of the share capital.
All conditions of the offer, including the minimum acceptance threshold of 65%, were fulfilled by the end of the acceptance period. The settlement of the shares tendered during the initial acceptance period is scheduled for May 23. "With all offer conditions fulfilled, Novartis can now begin the necessary steps to progress the integration of MorphoSys, including full access to pelabresib (CPI-0610), a novel BET inhibitor in combination with ruxolitinib for patients with myelofibrosis.
The integration also allows full access to tulmimetostat (CPI-0209), an early-stage investigational dual inhibitor of EZH1 and EZH2 currently being tested in patients with solid tumors or lymphomas, as well as a broad portfolio of partnered assets, some of which are in partnership with Novartis, including ianalumab (VAY736). In the context of the integration Novartis continues to progress the workstreams for implementation of both a delisting of MorphoSys and a domination and profit and loss transfer agreement with MorphoSys," the company stated.
